- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| THARIMMUNE Aktie jetzt für 0€ handeln | |||||
| Di | Tharimmune Inc.: Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors | 175 | ACCESS Newswire | BRIDGEWATER, NJ / ACCESS Newswire / April 15, 2025 / Tharimmune, Inc. (NASDAQ:THAR), a clinical-stage biotechnology company advancing novel solutions in immunology and oncology, today announced the... ► Artikel lesen | |
| 07.04. | Tharimmune Inc.: Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology | 164 | ACCESS Newswire | BRIDGEWATER, NJ / ACCESS Newswire / April 7, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today... ► Artikel lesen | |
| 04.04. | Tharimmune, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 31.03. | FDA greenlights Tharimmune's drug application pathway | 3 | Investing.com | ||
| 31.03. | Tharimmune Inc.: Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure | 160 | ACCESS Newswire | -Received positive feedback on New Drug Application submission via the 505(b)(2) pathway-Company leveraging existing human pharmacokinetic data with TH104-Advancing CMC plan to meet requirements of... ► Artikel lesen | |
| 24.03. | Tharimmune Inc.: Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha | 373 | ACCESS Newswire | BRIDGEWATER, NJ / ACCESS Newswire / March 24, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today... ► Artikel lesen | |
| 04.03. | Tharimmune unveils novel cancer treatment HS1940 | 2 | Investing.com | ||
| 04.03. | Tharimmune Inc.: Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology | 208 | ACCESS Newswire | BRIDGEWATER, NJ / ACCESS Newswire / March 4, 2025 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today... ► Artikel lesen | |
| 27.02. | Tharimmune, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 27.01. | Tharimmune Inc.: Tharimmune to Present at the Microcap Conference 2025 | 230 | ACCESS Newswire | BRIDGEWATER, NJ / ACCESS Newswire / January 27, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology... ► Artikel lesen | |
| 19.12.24 | Tharimmune files to sell 1.44 million shares of common stock by selling shareholders | 2 | Seeking Alpha | ||
| 16.12.24 | Tharimmune plans Phase 2 trial for itch treatment TH104 | 4 | Investing.com | ||
| 16.12.24 | Tharimmune, Inc.: Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update | 235 | ACCESS Newswire | BRIDGEWATER, NJ / ACCESSWIRE / December 16, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology... ► Artikel lesen | |
| 06.12.24 | Tharimmune announces $2.02M private placement; shares up | 2 | Seeking Alpha | ||
| 06.12.24 | Tharimmune secures $2.02 million in private funding | 2 | Investing.com | ||
| 06.12.24 | Tharimmune, Inc.: Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs | 413 | ACCESS Newswire | BRIDGEWATER, NJ / ACCESSWIRE / December 6, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology... ► Artikel lesen | |
| 06.12.24 | Tharimmune, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.11.24 | Tharimmune, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 18.11.24 | Tharimmune Inc.: Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting to Support TH104 for Chronic Pruritus in Chronic Liver Disease | 270 | ACCESS Newswire | Significant correlation shown between blood levels and symptom relief; TH104 was well tolerated with no unexpected treatment-emergent adverse eventsPhase 2 preliminary data for chronic pruritus in primary... ► Artikel lesen | |
| 13.11.24 | Tharimmune erhält europäisches Patent für Krebstherapie-Technologie | 2 | Investing.com Deutsch |
Seite:
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 35,980 | -1,91 % | Qiagen NV-Aktie gewinnt 1,38 Prozent (35,71 €) | An der Börse notiert die Aktie von Qiagen NV aktuell etwas fester. Das Papier kostete zuletzt 35,71 Euro. Ein Kursplus von 1,38 Prozent steht gegenwärtig für die Qiagen NV-Aktie zu Buche. Das Wertpapier... ► Artikel lesen | |
| NUVALENT | 71,64 | +2,39 % | Nuvalent, Inc. - 8-K, Current Report | ||
| EVOTEC | 6,396 | +9,90 % | EQS-News: Evotec SE stellt neue Strategie vor und gibt Ausblick für 2025 gestützt durch starkes Ergebnis im 4. Quartal 2024 | EQS-News: Evotec SE
/ Schlagwort(e): Jahresbericht
Evotec SE stellt neue Strategie vor und gibt Ausblick für 2025 gestützt durch starkes Ergebnis im 4. Quartal 2024
17.04.2025... ► Artikel lesen | |
| ADMA BIOLOGICS | 21,310 | +0,38 % | Why ADMA Biologics, Inc. (ADMA) Skyrocketed On Tuesday? | ||
| BEAM THERAPEUTICS | 17,000 | +2,29 % | Cathie Wood's ARK ETF focuses on Beam Therapeutics, Coinbase stock | ||
| TEMPUS AI | 40,450 | 0,00 % | Illumina, Tempus AI To Collaborate To Accelerate Genomic AI Innovation | SAN DIEGO (dpa-AFX) - Illumina Inc. (ILMN) and Tempus AI, Inc. (TEM), Tuesday announced a collaboration to accelerate clinical adoption of next-generation sequencing tests through novel evidence... ► Artikel lesen | |
| ARVINAS | 8,600 | 0,00 % | Pre-market Movers: 2seventy bio, Sonoma Pharmaceuticals, Tenon Medical, Arvinas, NET Power Inc. | LONDON (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 09.00 A.M. ET).In the Green 2seventy bio, Inc. (TSVT) is up over 76% at $4.93.
Sonoma... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 24,620 | 0,00 % | Here's Why Summit Therapeutics Stock Soared 15% on Friday | ||
| BIONTECH | 85,55 | -1,67 % | BioNTech-Aktie: Das muss man wirklich wissen! | News von Trading-Treff.de BioNTech hat sich sehr stark in die neue Woche eingeklinkt. Das Unternehmen konnte ein Plus in Höhe von 2,6 % verzeichnen. Schon am Freitag war es an der US-Börse NASDAQ um... ► Artikel lesen | |
| 89BIO | 6,060 | +2,89 % | 89bio, Inc.: 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 21,770 | 0,00 % | JMP maintains $87 target on Structure Therapeutics shares | ||
| RECURSION PHARMACEUTICALS | 5,485 | 0,00 % | Recursion lizenziert HealthVerity-Echtweltdaten für klinische Studien | ||
| ENLIVEN THERAPEUTICS | 16,530 | +2,73 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update | Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues
Expected monotherapy and combination data from the ELVN-002 Phase 1... ► Artikel lesen | |
| AMGEN | 243,65 | -0,06 % | Amgen-Aktie: Kurs fällt ab (237,5811 €) | Das Wertpapier von Amgen notiert heute ein wenig leichter. Die Aktie notiert derzeit bei 269,98 US-Dollar. Für die Amgen-Aktie steht gegenwärtig ein Abschlag von 4,48 Prozent zu Buche. Das Wertpapier... ► Artikel lesen | |
| BIOVENTUS | 7,820 | 0,00 % | Bioventus, Inc.: Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results | Accelerated fourth quarter sales growth to 13.5%Fourth quarter gross margin expanded 310 bps and adjusted gross margin* expanded 230 bpsFourth quarter cash from operations of $19.3 million increased... ► Artikel lesen |
Das Unternehmen THARIMMUNE INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,030 (+2,73 %) liegt der Kurs bei 1,130 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu THARIMMUNE INC finden Sie auf Wallstreet Online.
